Answers are grounded in this paper and cite their sources.
Core binding factor (CBF) acute myeloid leukemia (AML), defined by the cytogenetic abnormalities t(8;21)(q22;q22) and inversion(16)(p13;q22)/t(16;16)(p13;q22) chromosomal changes, is considered a favorable risk AML, with an estimated 5-year overall survival (OS) rate of ≈70%.1, 2 Among patients with CBF-AML, outcomes are usually worse in t(8;21) than in inversion 16.3 Overall, CBF-AML comprises around 10%–15% of all AML cases.1 The addition of gemtuzumab ozogamicin (GO) to chemotherapy have improved outcomes significantly, from a 5-year OS rate of 50%–55% to 75%.4 Non-randomized data indicate better relapse-free survival (RFS) with the addition of a second nucleoside analog like fludarabine, to cytarabine-based regimens.4-6 Two variables, one at baseline and one on treatment can prognosticate outcomes in CBF-AML. The first is the presence of concurrent kinase pathway mutations (KIT, RAS, FLT3) that negatively affect survival outcomes,7, 8 particularly relapse. The second is the ability to precisely assess measurable residual disease (MRD) using quantitative polymerase chain reaction (PCR) for unique fusion transcripts. This aids in the dynamic monitoring of response to therapy as well as detecting and treating imminent relapse after therapy.9 The attainment of optimal PCR response (OPR) of <0.1% PCR transcripts (at a level of detection of 10−4) after induction (C1) and <0.01% during or following consolidation has led to improved relapse-free survival (RFS).10 These OPR values are similar to the ones reported by the Medical Research Council (MRC).11 In this study, we evaluated the association of the presence or absence of kinase mutations on OPR and the association between achievement of OPR in two different regimens used at our institution, one adding GO to fludarabine and high-dose cytarabine (FLAG-GO), and the other replacing GO with idarubicin (FLAG-IDA), which was used when GO became unavailable after its temporary withdrawal from US markets during 2010–2017 (Figure S1). The treatment regimens have been detailed previously.5, 6 The study was approved by the institutional review board and informed consent was obtained in accordance with institutional guidelines and the Declaration of Helsinki. RFS was calculated from the time of response until relapse or death; OS was calculated from the time of diagnosis until death. Both time-to-outcome endpoints were censored at last follow up. From April 2007 to December 2019, 174 patients, who were treated on an ongoing prospective phase II clinical trial (NCT00801489) of FLAG-GO (N = 65, 37%) or FLAG-IDA (N = 109, 63%) were included in this study. The FLT3 (TKD and ITD), RAS, and KIT mutation status was captured for each patient. At a median follow up of 92 months, the median RFS of the whole cohort was 148 months (95% CI = 101-not estimable) and median OS was not reached (NR) (95% CI = 110 months-NR). Baseline disease and treatment characteristics were well balanced between both the two treatment groups (Table S1), except for a higher percentage of KIT mutations in the FLAG-IDA group compared with the FLAG-GO group (26% vs. 13%). Effect of kinase mutations on OPR: A total of 156 (90%) patients had a complete kinase mutation data, of whom 60 (39%) patients had no mutations and 5 (3%) patients had all three mutations. Individually, 35/170 (21%) patients had FLT3 mutations (TKD = 22, ITD = 10, ITD + TKD = 3), 59/159 (37%) patients had RAS mutations and 36/168 (21%) patients had KIT mutations (Figure S2). Among the 144 patients with available post C1 PCR data (i.e., C1 of FLAG-based therapy) there were no difference in the rates of early OPR based on the presence or absence of any kinase mutation. Early OPR was 55% versus 52% for RAS-mutated and unmutated disease(p = .73), 55% versus 52% (p = .99) for KIT-mutated and unmutated disease, and 66% versus 50% (p = .16) for FLT3-mutated and unmutated disease. For later PCR time points (i.e., during or after consolidation), data were available for 139 patients, of whom 100 (72%) patients had an OPR at any time. The depth of OPR during or after consolidation is one log-level deeper than after C1 (early OPR) as described above. We used the best PCR response captured post C2 (first consolidation) through end of therapy for the later PCR response assessments. Like with early OPR, there were no differences in the rates of subsequent OPR with any of the kinase mutations: OPR 75% versus 72% (p = .7) for RAS-mutated and unmutated, 61% versus 77% (p = .07) for KIT-mutated and unmutated, and 76% versus 73% (p = .83) for FLT3-mutated and unmutated. Patients with no kinase mutations had similar rates of early (54% vs. 43%, p = .19) or later OPR (69% vs. 79%, p = .31), compared to patients with kinase mutations. Seventeen (10%) patients had >1 RAS mutation; there were no differences in rates of early OPR (59% vs. 51%, p = .77) and later OPR (63% vs. 79%, p = .31) among patients with single or multiple RAS mutations. Logistic regression analysis including age, CBF karyotype, presence of additional cytogenetic abnormalities (ACA) (other than isolated-Y), kinase mutations, and chemotherapy regimen as covariates, showed that only the presence of FLT3 mutation (odds ratio [OR], 2.38, 95% CI, 1.08–5.48) and the use of FLAG-GO (OR, 2.63, 95% CI, 1.3–5.26) were favorably associated with early OPR. Using the same covariates for later OPR, FLAG-GO was favorable (OR = 12.5, 95% CI = 4.55–50) and the presence of KIT mutation trended toward reduced odds of OPR (OR = 0.47, 95% CI = 0.2–1.00, p = .06). On multivariate analysis, only the therapy arm remained significant, favoring FLAG-GO (OR = 17, 95% CI = 4.34–111). Effect of cadence of OPR: Given the importance of OPR in dynamically evaluating therapy response, we assessed the time points of OPR and their effect on survival. Based on the timing of OPR we stratified patients into four groups as follows: G1—early optimal, late sub-optimal; G2—early suboptimal, late optimal; G3—early and late optimal, and G4—both time-points suboptimal or early death without response assessment (Table S2). Early and later PCR data were available for 158 (91%) patients; 5 (3%) patients were in G1, 40 (25%) in G2, 75 in G3 (47%) and 38 (24%) in G4 (Figure S3). The median RFS in the four groups were 44.2 months for G1, not reached (NR) for G2 and G3, and 20.1 months for G4, respectively (p log rank for trend <.001). Median OS was 102 months for G1, NR for G2 and G3, and 86.4 months for G4, respectively (p log rank for trend = .003) (Figure 1). Patients in groups G2 and G3 had a better RFS (NR vs. 20.1 months, p = .001) and OS (NR vs. 86.4 months) compared with patients in groups G1 and G4. To further ascertain if persistent OPR (G3) was beneficial over delayed attainment of OPR (G2), we compared these two groups and found no difference in terms of median RFS or OS but G3 trended toward improved 10 years RFS of 68% versus 50% and OS of 73% versus 60% over G2 (Figure S4). We used Cox proportional hazard model that included patient age, treatment arm, and the patient response groups as described above (G1–G4) to study factors that affected RFS and OS. For RFS, older age (HR, 1.03, 95% CI, 1.01–1.05, p = .0002) was associated with higher hazards of relapse, while the use of FLAG-GO compared to FLAG-IDA (HR = 0.51, 95% CI = 0.27–0.94, p = .03), G3 (HR, 0.40, 95% CI, 0.22–0.75, p = .004) (but not G1 [HR = 0.88, 95% CI = 0.25–2.3] or G2 [HR = 0.57, 95% CI = 0.29–1.11]) compared with G4 were associated with lower hazards of relapse. For OS, older age (HR, 1.04, 95% CI, 1.02–1.06, p < .0001) was associated with worse survival, while G2 (HR = 0.46, 95% CI = 0.20–0.98, p = .04) and G3 (HR, 0.36, 95% CI, 0.18–0.72, p = .004) compared to G4 were associated with better OS (Figure S5). Previous studies have shown that kinase mutations are associated with inferior survival outcomes in CBF-AML, however, their effect seemed predominant in patients with t(8;21) CBF-AML and in those treated with non-FLAG-based regimens.7, 12-15 In our study, the presence of kinase mutations was not associated with differences in OPR rates, while the use of FLAG-GO compared with FLAG-IDA improved the rates of both early and late OPR. The presence of multiple RAS mutations also did not affect the attainment of OPR. Using the PCR response timepoints and studying their impact on RFS and OS, our data show the importance of achieving an optimal PCR response at <0.01% during/after consolidation over isolated early OPR <0.1%. Thus, patients on FLAG-based regimens who have suboptimal post C1 PCR can still be maintained on the same regimen and be assessed for mid/post consolidation PCR responses to decide on the adequacy of therapy. In summary, our data demonstrate that the presence of kinase mutations in patients with CBF-AML treated with FLAG-based regimens was not an adverse prognostic factor. The attainment of PCR <0.01% during/after consolidation improved RFS and was more important than achieving early OPR (post C1 PCR <0.1%). FLAG-GO was superior to FLAG-IDA in improving OPR and RFS. Further studies are needed to understand the optimal therapy for patients who fail to attend OPR during/after consolidation, including the need for allogeneic stem cell transplantation. Jayastu Senapati designed the manuscript, collected and analyzed the data, and wrote the manuscript. Tareq Abuasab and Fadi G. Haddad collected and analyzed the data. Mark A. Brandt collected the data. Gautam Borthakur conceptualized and designed the manuscript, analyzed the data, and edited the manuscript. All authors critically reviewed the manuscript and approved the final version. Tapan Kadia: Research grants—Amgen, Ascentage, Astellas, AstraZeneca, BMS, Cellenkos, Pulmotech, Genfleet. Personal fees from—Agios, Cure, Daichi Sankyo, Genzyme, Liberum, Novartis, Sanofi-Aventis. Research grants and personal fees—Abbvie, Genetech, Jazz Pharmaceuticals, Pfizer. Courtney DiNardo: Research grants—Abbvie, Agios/Servier, Astex, Calithera, Celgene/BMS, Cleave, Daiichi-Sankyo, ImmuneOnc, Loxo. Honoraria/consulting fees—Abbvie, Agios/Servier, Astellas, Celgene/BMS, Cleave, Foghorn, Genentech, Novartis, Notable Labs, Takeda. Naveen Pemmaraju: Research grants—Novartis, Stemline Therapeutics, Samus Therapeutics, Abbvie, Cellectics, Affymetrix/Thermo Fisher Scientific, Daiichi Sankyo, Plexxikon, MustangBio. Honoraria—Incyte, Novartis, LFB Biotechnologies, Stemline Therapeutics, Celgene, Abbvie, MustangBio, Roche Molecular Diagnostics, Blueprint Medicines, DAVA Pharmaceuticals, Springer Science+Business Media LLC, Aptitude Health, NeoPharm, CareDX. Consulting or advisory role—Blueprint Medicines, Pacylex Pharmaceuticals Inc., Immunogen, Mristol Myers Squibb, Clearview Healthcare Partners, Astellas Pharma US Inc., Protagonist Therapeutics, Triptych Health Partners, CTI BioPharma Corp. Travel/accommodation expenses—Stemline Therapeutics, Celgene, Abbvie, DAVA oncology, MustangBio. Naval Daver: Consulting or Advisory Role-Celgene, Agios, Jazz Pharmaceuticals, Pfizer, AbbVie, Astellas Pharma, Daiichi Sankyo, Novartis, Bristol Myers Squibb, Amgen, Immunogen, Genentech, Servier, Syndax, Trillium Therapeutics, Gilead Sciences, Arog, Shattuck Labs. Research Funding- Bristol Myers Squibb, Pfizer, Immunogen, Genentech, AbbVie, Astellas Pharma, Servier, Daiichi Sankyo, Gilead Sciences, Amgen, Trillium Therapeutics, Hanmi, Trovagene, FATE Therapeutics, Novimmune, GlycoMimetics. Hagop Kantarjian: Research grants- AbbVie, Agios, Amgen, Ariad, Astex, BMS, Cyclacel, Daiichi-Sankyo, Immunogen, Jazz Pharma, Novartis, Pfizer, Actinium, and Takeda. Appendix S1. Supporting Information Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
No takes yet. Share an insight, caveat, or question.
Senapati et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: